Inspire Medical’s shares fell 7.9% despite Q3 revenue and adjusted operating income coming in slightly ahead of management’s expectations. The call’s emphasis on helping patient flow and building momentum for 2027, alongside the need to invest through 2026, suggests that near-term growth remains a concern; the transcript does not provide a specific guidance cut.
- Revenue increased 3% sequentially. Management also cited strong operating cash flow, but gave no revenue or earnings figures in the provided transcript.
- Inspire is investing in patient access and conversion, with additional field roles planned in approximately 40 high-potential markets and further investment expected in Q4.
- Management said the final 2027 OPPS reimbursement rule was still pending, expected later that week; the July proposal showed a significant increase.
- A new Category I CPT code for single-lead hypoglossal nerve stimulation is scheduled to take effect January 1, 2028. Reimbursement valuation remains under review.
- Inspire V adoption was described as strong. Management cited improved inspiratory overlap in early assessments, while the transcript provides no specific clinical outcome figures.
Community Discussion